IPSEN (EPA:IPN) Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
Transparency directive : regulatory news
13/11/2023 22:30
IPSEN's latest news
15/02/2024 10:00
13/02/2024 22:08
22/01/2024 23:00
07/12/2023 18:49
13/11/2023 22:30
06/10/2023 18:00
04/09/2023 07:00
01/09/2023 07:00
22/08/2023 18:00
16/08/2023 21:32
Other stories
29/04/2024 20:18
29/04/2024 20:25
29/04/2024 17:02
29/04/2024 16:01
29/04/2024 16:19
29/04/2024 10:17
29/04/2024 09:46
29/04/2024 16:08
29/04/2024 15:44
29/04/2024 18:44
29/04/2024 12:22
27/04/2024 10:53
29/04/2024 16:01
29/04/2024 18:57
29/04/2024 19:23
29/04/2024 15:36
29/04/2024 17:20
29/04/2024 16:48
29/04/2024 15:03
29/04/2024 14:30
29/04/2024 16:50
29/04/2024 17:43
29/04/2024 07:00
29/04/2024 19:44
29/04/2024 17:24
29/04/2024 18:42
29/04/2024 20:32
29/04/2024 19:45
29/04/2024 18:38
29/04/2024 14:48
28/04/2024 19:21
29/04/2024 12:00
29/04/2024 12:14
28/04/2024 12:18
29/04/2024 14:39
29/04/2024 19:43
29/04/2024 17:12